Showing results (161-170 of 589) with videos related to
Sort By:
Pageof 59
Cancer|July 6, 2018
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanomaAlexander T Faje, Donald Lawrence, Keith Flaherty, et al.Radiology|July 21, 2007
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in miceAntoine Hakimé, Andrew Hines-Peralta, Himaja Peddi, et al.Radiology|February 27, 2009
Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findingsMaryellen R M Sun, Long Ngo, Elizabeth M Genega, et al.Cancer|June 28, 2012
Number of primary melanomas is an independent predictor of survival in patients with metastatic melanomaRajmohan Murali, Philip T Brown, Richard F Kefford, et al.Immunotherapy|January 30, 2020
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinomaApoorva Ambavane, Shuo Yang, Michael B Atkins, et al.Molecular Cancer Therapeutics|October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanomaDavid J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.Bioactive Materials|January 21, 2025
Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) against Kit -mutant melanomaKishwor Poudel, Zhenyu Ji, Ching-Ni Njauw, et al.Journal for Immunotherapy of Cancer|July 24, 2023
Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug developmentHarriet M Kluger, Hussein Tawbi, David Feltquate, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2010
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinomaDaniel C Cho, Matthew B Cohen, David J Panka, et al.Cancer|March 28, 2006
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacyKen Wyman, Michael B Atkins, Victor Prieto, et al.Pageof 59